New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.
LONDON, May 11 (Reuters) - AstraZeneca Plc's experimental heart drug Brilinta has beaten Sanofi-Aventis SA and Bristol-Myers Squibb Co's blockbuster Plavix in a pivotal clinical trial, lifting its ...
LONDON (Reuters) - AstraZeneca Plc's experimental heart drug Brilinta has beaten Sanofi-Aventis SA and Bristol-Myers Squibb Co's blockbuster Plavix in a pivotal clinical trial, lifting its shares ...